Free tool
FAERS Monitor: Ajovy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761089 or its brand name (Ajovy, Fremanezumab-Vfrm). Reports on generic versions are filed under their own applications.
Reports
11,839
Serious
3,963
33% of reports
Hospitalization
869
Death reported
117
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- accidental exposure to product1,501
- injection site pain1,358
- migraine1,114
- drug ineffective951
- headache778
- injection site erythema685
- device leakage576
- device malfunction521
- fatigue518
- nausea518
- injection site pruritus511
- injection site swelling462
- drug dose omission by device455
- dizziness414
- incorrect dose administered by device402
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 177 |
| 2019 | 1,390 |
| 2020 | 1,047 |
| 2021 | 1,421 |
| 2022 | 1,590 |
| 2023 | 1,420 |
| 2024 | 2,163 |
| 2025 | 1,484 |
| 2026 | 1,140 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,320 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| incorrect dose administered by deviceSignal | 402 | 27.7 | 25.1 | 10,157 |
| accidental exposure to productSignal | 1,501 | 26.2 | 25.0 | 36,068 |
| device leakageSignal | 576 | 23.9 | 22.1 | 12,477 |
| migraineSignal | 1,114 | 21.0 | 19.8 | 21,009 |
| injection site pruritusSignal | 511 | 13.6 | 12.5 | 5,951 |
| device malfunctionSignal | 521 | 13.3 | 12.2 | 5,871 |
| injection site swellingSignal | 462 | 10.8 | 9.8 | 4,076 |
| drug dose omission by deviceSignal | 455 | 10.4 | 9.5 | 3,838 |
| injection site erythemaSignal | 685 | 9.9 | 9.2 | 5,446 |
| injection site painSignal | 1,358 | 7.9 | 7.5 | 8,256 |
| headacheSignal | 778 | 2.2 | 2.1 | 527 |
| dizziness | 414 | 1.5 | 1.3 | 64 |
| drug ineffective | 951 | 1.3 | 1.2 | 63 |
| fatigue | 518 | 1.2 | 1.1 | 15 |
| nausea | 518 | 1.2 | 1.1 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.